# A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)

> **NCT01208181** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 1404 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Etoricoxib 60 mg
- **DRUG:** Etoricoxib 90 mg
- **DRUG:** Placebo to Etoricoxib 60 mg
- **DRUG:** Placebo to Etoricoxib 90 mg

## Key facts

- **NCT ID:** NCT01208181
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-27
- **Primary completion:** 2014-06-09
- **Final completion:** 2014-07-29
- **Target enrollment:** 1404 (ACTUAL)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01208181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01208181, "A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01208181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*